PDS Biotechnology Corporation
PDSB · NASDAQ
Bulios Fair Price
$0.58
28.0% downside
Current Price
$0.81
According to Bulios Fair Price, PDSB is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
About the company
PDS Biotechnology Corporation is a biotechnology company focused on developing immunotherapeutic drugs for the treatment of various types of cancer and infectious diseases. Their main product is a platform called Versamune™, which combines antigen presentation with immune response activation, allowing for the creation of effective vaccines and immunotherapies. This platform is designed to activate and bolster the patient's immune system to fight against cancer and infections. PDS Biotechnology Corporation aims to develop innovative therapeutic approaches that can improve the treatment of these serious diseases and contribute to better patient health.
Sector
Healthcare
Industry
Biotechnology
CEO
Frank K. Bedu-Addo
Employees
21
Headquarters
Princeton
Upcoming events
Earnings
Upcoming earnings report